IRMD - アイラディメッド （iRadimed Corporation） アイラディメッドIRMDのチャート
IRMDの企業情報
| symbol | IRMD |
|---|---|
| 会社名 | iRadimed Corp （アイラディメッド） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 アイラジメド（iRadimed Corporation）は磁気共鳴イメージング（MRI）プロシージャーに使用するのに安全である非磁性静脈内（IV）輸液ポンプシステムのプロバイダーである。同社の電気医療デバイス及びポンプは、無線周波数（RF）ノイズを発生し、干渉を作成し、MRIを駆動するsmagnetの存在下で運転するのは危険である磁気・電子部品により構成される。同社の「mRidium」（3850/3860+）IVポンプシステムは様々なMRIプロシージャーにおいて、麻酔やその他の静脈内輸液をお届けするために、非鉄部品、セラミック超音波モータ、非磁性携帯スタンド及びその他の特殊機能により構成される。同社のポンプ・ソリューションは、MRIスキャンの前・中・後に静脈内輸液を提供するためのシームレスなアプローチを提供する。平成26年3月31日現在、同社は全世界において、約1917のインストールされたIV注入ポンプシステムを持っている。 アイラディメッドは、核磁気共鳴画像法(MRI)対応製品の製造・販売会社。同社の製品「MRidium 3860+」MRI適合の静脈内(IV)注入ポンプシステムは、各種のMRI過程で麻酔や他の静注輸液を患者に行き渡らせるために、非鉄部品、セラミック超音波モ―タ、非磁性モバイルスタンドで構成され、世界的に使用されている。 IRADIMED CORPORATION is a leader in the development of innovative magnetic resonance imaging ('MRI') compatible medical devices. It's the only known provider of a non-magnetic intravenous ('IV') infusion pump system that is specifically designed to be safe for use during MRI procedures. The Company is the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Its patented MRidium® MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, uniquely-designed non-ferrous parts and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Its pump solution provides a seamless approach that enables accurate, safe and dependable fluid delivery before, during and after an MRI scan, which is important to critically-ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated to remain immobile during an MRI scan. |
| 本社所在地 | 1025 Willa Springs Drive Winter Springs FL 32708 USA |
| 代表者氏名 | Roger Susi ロジャー・スージ |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer Founder |
| 電話番号 | +1 407-677-8022 |
| 設立年月日 | 33786 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2014年 |
| 従業員数 | － |
| url | www.iradimed.com |
| nasdaq_url | https://www.nasdaq.com/symbol/irmd |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 4.47370 |
| 終値（lastsale） | 30.51 |
| 時価総額（marketcap） | 325850827.32 |
| 時価総額 | 時価総額（百万ドル） 277.36300 |
| 売上高 | 売上高（百万ドル） 26.87960 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 247.86011 |
| 当期純利益 | 当期純利益（百万ドル） 3.04610 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Iradimed Corp revenues increased 36% to $14.5M. Net income increased from $124K to $2.2M. Revenues reflect United States segment increase of 28% to $11.7M International segment increase of 82% to $2.8M. Net income benefited from Research and development decrease of 25% to $700K (expense) Stock-based compensation Sales and marke decrease of 27% to $162K (expense). |
IRMDのテクニカル分析
IRMDのニュース
IRADIMED CORPORATION Issues Urgent Medical Device Correction 2023/02/24 21:15:00 GlobeNewswire
Letter Notifying Customers of Potential Issues with MRidium 1057 MRI Syringe Adapter Set Letter Notifying Customers of Potential Issues with MRidium 1057 MRI Syringe Adapter Set
IRadimed: Revise To Buy With Exceptional Incremental ROIC In Q4 (NASDAQ:IRMD) 2023/02/10 15:45:08 Seeking Alpha
IRadimed came in with a strong set of Q4 and full-year numbers. Click here to read more about IRMD stock.
IRadimed Q4: A Bottom-Line Beat, A Special Cash Dividend, Maintain Buy 2023/02/08 10:32:21 Seeking Alpha
IRadimed reported strong Q4:22 results, essentially driven by strength in its monitors segment. See why we reiterate IRMD stock as a buy.
IRadimed Corp PT Raised to $51 at Singular Research 2023/02/06 20:04:01 Investing.com
https://www.investing.com/news/pro/iradimed-corp-pt-raised-to-51-at-singular-research-432SI-2996393
IRadimed Corporation (IRMD) Q4 2022 Earnings Call Transcript 2023/02/02 19:05:26 Seeking Alpha
IRadimed Corporation (NASDAQ:NASDAQ:IRMD) Q4 2022 Earnings Conference Call February 2, 2023 11:00 AM ETCompany ParticipantsRoger Susi - President & CEOJack Glenn – CFOConference Call…
IRadimed Corporation (IRMD) Q4 2022 Earnings Call Transcript 2023/02/02 19:05:26 Seeking Alpha
IRadimed Corporation (NASDAQ:NASDAQ:IRMD) Q4 2022 Earnings Conference Call February 2, 2023 11:00 AM ETCompany ParticipantsRoger Susi - President & CEOJack Glenn – CFOConference Call…
iRadimed Q4 Non-GAAP EPS, revenue of $14.9M 2023/02/02 13:34:35 Seeking Alpha
iRadimed press release (IRMD): Q4 Non-GAAP EPS of $0.32 (vs
iRadimed declares $1.05 special dividend (NASDAQ:IRMD) 2023/02/02 13:05:25 Seeking Alpha
iRadimed (NASDAQ:IRMD) declares $1.05/share special dividend.Payable Feb. 21; for shareholders of record Feb. 13; ex-div Feb.
IRADIMED CORPORATION Announces Fourth Quarter and Full Year 2022 Financial Results and Announces Special Cash Dividend 2023/02/02 13:00:00 GlobeNewswire
WINTER SPRINGS, Fla., Feb. 02, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD) announced today its financial results for the fourth quarter and year ended December 31, 2022. The Company also announced that its Board of Directors approved a special cash dividend of $1.05 per share on the Company''s outstanding common stock. This special cash dividend is payable on February 21, 2023, to shareholders of record at the close of business on February 13, 2023. The Company is a leader in the development of innovative magnetic resonance imaging ("MRI") medical devices and the only known provider of a non-magnetic intravenous ("IV") infusion pump system and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.
iRadimed''s Earnings Outlook 2023/02/01 21:01:57 Benzinga
iRadimed (NASDAQ: IRMD ) is set to give its latest quarterly earnings report on Thursday, 2023-02-02. Here''s what investors need to know before the announcement. Analysts estimate that iRadimed will report an earnings per share (EPS) of $0.28. iRadimed bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next … Full story available on Benzinga.com
iRadimed''s Return On Capital Employed Insights 2022/11/22 14:50:10 Benzinga
According to Benzinga Pro, during Q3, iRadimed (NASDAQ: IRMD ) earned $3.43 million, a 5.74% increase from the preceding quarter. iRadimed also posted a total of $13.41 million in sales, a 5.38% increase since Q2. In Q2, iRadimed earned $3.24 million, and total sales reached $12.72 million. Why Is ROCE Significant? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of … Full story available on Benzinga.com
iRadimed: Reduce To Hold, Price Visibility Around $28 More Certain (NASDAQ:IRMD) 2022/11/18 20:35:11 Seeking Alpha
iRadimed continues to re-rate to the downside despite robust fundamentals last quarter.
IRadimed Corp PT Raised to $45 at Singular Research 2022/11/08 10:15:01 Investing.com
https://www.investing.com/news/pro/iradimed-corp-pt-raised-to-45-at-singular-research-432SI-2935721
IRadimed Corporation (IRMD) CEO Roger Susi on Q3 2022 Results - Earnings Call Transcript 2022/11/06 02:03:04 Seeking Alpha
IRadimed Corporation (NASDAQ:NASDAQ:IRMD) Q3 2022 Earnings Conference Call November 03, 2022 11:00 AM ET Company Participants Roger Susi - President and Chief Executive Officer Jack Glenn -…
Recap: iRadimed Q3 Earnings 2022/11/03 11:46:11 Benzinga
iRadimed (NASDAQ: IRMD ) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings iRadimed beat estimated earnings by 20.83%, reporting an EPS of $0.29 versus an … Full story available on Benzinga.com